Pexelizumab
Humanized (from mouse) | |
|---|---|
| Target | Complement component 5 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Pexelizumab is a
single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]
Current status
Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[5]
References
- ^ Clinical trial number NCT00088179 for "Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass" at ClinicalTrials.gov
- ^ Clinical trial number NCT00091637 for "Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction" at ClinicalTrials.gov
- PMID 18954626.
- PMID 15331798.
- ^ Mitchell S (2 January 2007). "Analysis: Alexion's pexelizumab fails". United Press International.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |